Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2013-04-24 Annual Report
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
Jaarverslag Statutaire Jaarrekening.pdf
Annual Report Classification · 100% confidence The document is titled 'Jaarverslag van de Raad van Bestuur over de statutaire jaarrekening' (Annual Report of the Board of Directors on the statutory annual accounts) for the company ThromboGenics NV. It contains detailed financial performance data for the fiscal year 2012, including profit/loss figures, revenue breakdowns, operational costs, capital increases, and risk management disclosures. As it provides comprehensive financial statements and management analysis for a full fiscal year, it is classified as an Annual Report (10-K). FY 2012
2013-04-24 Dutch
Jaarverslag Geconsolideerde Jaarrekening.pdf
Management Reports Classification · 99% confidence The document is titled 'Jaarverslag van de Raad van Bestuur over de geconsolideerde jaarrekening' (Annual Report of the Board of Directors on the consolidated annual accounts) and contains detailed financial statements, including the Income Statement ('Verlies- en winstrekening'), Cash Flow analysis, Balance Sheet details ('balanstotaal'), and extensive notes on capital changes and risks for the fiscal year 2012. This content structure is characteristic of a comprehensive annual financial report. Although the text is in Dutch, the content strongly aligns with the scope of a full Annual Report, which corresponds to the '10-K' filing type in the US context, or its equivalent comprehensive annual filing in other jurisdictions. It is not merely an announcement (RPA) as it contains the full financial details.
2013-04-24 Dutch
jaarrek website zonder decimalen.pdf
Annual Report Classification · 100% confidence The document is a formal Belgian 'Jaarrekening' (Annual Accounts) for the company ThromboGenics. It includes structured financial statements (Balance Sheet/Balans), lists of directors, and auditor information. As it contains the full financial statements for the fiscal year, it qualifies as an Annual Report (10-K equivalent in this context). FY 2012
2013-04-24 Dutch
THR_AV_2013_-_ThromboGenics_oproeping_AV_2013_NL.pdf
AGM Information Classification · 100% confidence The document is explicitly titled "OPROEPING" (Call/Summons) and invites shareholders to attend the "jaarvergadering" (annual general meeting) scheduled for May 7, 2013. The text details the agenda, which includes discussing the annual report, approving the remuneration report, approving the statutory annual accounts for the year ended December 31, 2012, granting discharge to directors and the commissioner, and reappointing directors and the commissioner. It also outlines the conditions for participation and voting rights, and the process for submitting questions and proxies. This content perfectly matches the definition of materials shared during an Annual General Meeting (AGM). Therefore, the correct classification is AGM-R.
2013-04-24 Dutch
THROM_2275-4_JVSL_Fin_NL_DEF_LORES_09-04.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'Jaarverslag' (Annual Report) and contains comprehensive financial statements, including a consolidated balance sheet, profit and loss statement, management discussion, and auditor's responsibility statement for the fiscal year ending December 31, 2012. It is a full-length report rather than an announcement or summary, fitting the definition of an Annual Report (10-K). FY 2012
2013-04-24 Dutch
Persbericht_transparantieverklaringOF.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled 'PERSBERICHT' (Press Release) and discusses the receipt of a 'transparantiemelding' (transparency notification) regarding shareholdings from Oppenheimer Funds. It details the number of shares held by Oppenheimer Funds and lists other major shareholders. This type of filing, which reports changes in significant share ownership thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is short and serves as an announcement of this specific regulatory event.
2013-03-27 Dutch

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.